CRNX vs UNH

Crinetics Pharmaceuticals remains a high-conviction opportunity for 10x growth, building on its strong foundation. The Q4 2025 revenue beat for paltusotine signals robust initial commercial execution, de-risking its path to significant revenue in a multi-billion-dollar acromegaly market. The company boasts an exceptional cash runway exceeding $1.38 billion, providing strong financial stability. Wh...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...